Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
California-based Ambrx and Japan’s Astellas Pharma are joining to discover and develop antibody-drug conjugates for oncology. Ambrx will receive an up-front payment of $15 million from Astellas and could get up to $285 million in milestone payments. Ambrx creates ADCs using site-specific conjugation technology that allows the attachment of anticancer compounds to specific points on an antibody. It also has partnerships with Bristol-Myers Squibb, Eli Lilly & Co., and other firms.
This article has been sent to the following recipient: